Choosing between Novavax (NASDAQ: NVAX) and Moderna (NASDAQ: MRNA) might seem like a slam dunk in Moderna's favor. Based on market cap, Moderna is more than 16 times larger than Novavax. Moderna is generating a lot more revenue and earnings than Novavax is. It has a much broader pipeline as well. 

But this decision is absolutely not a slam dunk for Moderna. Actually, to extend the basketball analogy, it might even be more of a layup for Novavax. Here are three reasons why Novavax is a better stock to buy than Moderna right now.

Moderna's shares will likely enjoy at least a modest bump from the booster vaccine it's developing that targets the coronavirus omicron variant. There probably will even be two separate positive catalysts -- one when the U.S. government orders additional doses from Moderna that include the omicron boosters, and another when the company wins Emergency Use Authorization (EUA) for the boosters.

Continue reading

Source Fool.com